Carisma Therapeutics (NASDAQ:CARM) Insider Michael Klichinsky Sells 200,000 Shares of Stock

Carisma Therapeutics Inc. (NASDAQ:CARM) insider Michael Klichinsky sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $0.25, for a total transaction of $50,000.00. Following the sale, the insider owned 119,347 shares of the company’s stock, valued at approximately $29,836.75. This represents a 62.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Michael Klichinsky also recently made the following trade(s):

• On Friday, October 3rd, Michael Klichinsky sold 119,347 shares of Carisma Therapeutics stock. The shares were sold at an average price of $0.26, for a total transaction of $31,030.22.
• On Wednesday, October 1st, Michael Klichinsky sold 165,000 shares of Carisma Therapeutics stock. The shares were sold at an average price of $0.26, for a total transaction of $42,900.00.

Carisma Therapeutics Trading Down 3.4%

Shares of Carisma Therapeutics stock opened at $0.26 on Friday. Carisma Therapeutics Inc. has a twelve month low of $0.14 and a twelve month high of $1.27. The stock has a market cap of $10.90 million, a price-to-earnings ratio of -0.17 and a beta of 2.06. The company has a fifty day moving average price of $0.30 and a 200 day moving average price of $0.30.

Institutional Trading of Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Carisma Therapeutics Inc. (NASDAQ:CARM) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 200,000 shares of the company’s stock, valued at approximately $62,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.48% of Carisma Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CARM shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Carisma Therapeutics in a research note on Saturday, September 27th. Evercore ISI raised shares of Carisma Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 15th. Finally, D. Boral Capital reiterated a “buy” rating and set a $1.00 price objective on shares of Carisma Therapeutics in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1.93.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.